Immune biomarkers in the spectrum of childhood noncommunicable diseases

Skevaki, Chrysanthi, Van den Berg, Jolice, Jones, Nicholas, Garssen, Johan, Vuillermin, Peter, Levin, Michael, Landay, Alan, Renz, Harald, Calder, Philip C. and Thornton, Catherine A. 2016, Immune biomarkers in the spectrum of childhood noncommunicable diseases, Journal of allergy and clinical immunology, vol. 137, no. 5, pp. 1302-1316, doi: 10.1016/j.jaci.2016.03.012.

Attached Files
Name Description MIMEType Size Downloads

Title Immune biomarkers in the spectrum of childhood noncommunicable diseases
Author(s) Skevaki, Chrysanthi
Van den Berg, Jolice
Jones, Nicholas
Garssen, Johan
Vuillermin, PeterORCID iD for Vuillermin, Peter
Levin, Michael
Landay, Alan
Renz, Harald
Calder, Philip C.
Thornton, Catherine A.
Journal name Journal of allergy and clinical immunology
Volume number 137
Issue number 5
Start page 1302
End page 1316
Total pages 15
Publisher Elsevier
Place of publication Amsterdam, The Netherlands
Publication date 2016-05
ISSN 1097-6825
Keyword(s) biomarkers
mass spectrometry
noncommunicable diseases
Summary A biomarker is an accurately and reproducibly quantifiable biological characteristic that provides an objective measure of health status or disease. Benefits of biomarkers include identification of therapeutic targets, monitoring of clinical interventions, and development of personalized (or precision) medicine. Challenges to the use of biomarkers include optimizing sample collection, processing and storage, validation, and often the need for sophisticated laboratory and bioinformatics approaches. Biomarkers offer better understanding of disease processes and should benefit the early detection, treatment, and management of multiple noncommunicable diseases (NCDs). This review will consider the utility of biomarkers in patients with allergic and other immune-mediated diseases in childhood. Typically, biomarkers are used currently to provide mechanistic insight or an objective measure of disease severity, with their future role in risk stratification/disease prediction speculative at best. There are many lessons to be learned from the biomarker strategies used for cancer in which biomarkers are in routine clinical use and industry-wide standardized approaches have been developed. Biomarker discovery and validation in children with disease lag behind those in adults; given the early onset and therefore potential lifelong effect of many NCDs, there should be more studies incorporating cohorts of children. Many pediatric biomarkers are at the discovery stage, with a long path to evaluation and clinical implementation. The ultimate challenge will be optimization of prevention strategies that can be implemented in children identified as being at risk of an NCD through the use of biomarkers.
Language eng
DOI 10.1016/j.jaci.2016.03.012
Field of Research 111799 Public Health and Health Services not elsewhere classified
1107 Immunology
Socio Economic Objective 920499 Public Health (excl. Specific Population Health) not elsewhere classified
HERDC Research category C1 Refereed article in a scholarly journal
ERA Research output type C Journal article
Copyright notice ©2016, Crown Copyright
Persistent URL

Document type: Journal Article
Collections: Faculty of Health
School of Medicine
Connect to link resolver
Unless expressly stated otherwise, the copyright for items in DRO is owned by the author, with all rights reserved.

Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in TR Web of Science
Scopus Citation Count Cited 11 times in Scopus
Google Scholar Search Google Scholar
Access Statistics: 199 Abstract Views, 1 File Downloads  -  Detailed Statistics
Created: Wed, 24 Aug 2016, 16:08:42 EST

Every reasonable effort has been made to ensure that permission has been obtained for items included in DRO. If you believe that your rights have been infringed by this repository, please contact